Drugs / Anti-LeY- scFv-CD28-ζ vector
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01716364 | Jan 2010 → Dec 2013 | acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma | Peter MacCallum Cancer Centre, Australia | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-LeY- scFv-CD28-ζ vector | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01716364 ↗ |
| Route | Other | “After the modified T cells are infused into the patient” NCT01716364 ↗ |